Pan-cancer analysis identifies KANSL2 as a cell-cycle–associated regulator of tumor progression and immunity in liver hepatocellular carcinoma

Clinical and Experimental Medicine · Published 2026-07-26 · DOI 10.1007/s10238-026-02264-7

Free full text

Authors (8)

Nanbin Liu, Kun Li, Junqiao Feng, Shan Wang, Ji Li, Wenbin Yang, Senyang Li, Keping Feng

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Liu, N., Li, K., Feng, J., et al. (2026). Pan-cancer analysis identifies KANSL2 as a cell-cycle–associated regulator of tumor progression and immunity in liver hepatocellular carcinoma. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-026-02264-7

Related articles

• LRP8 drives cervical cancer lymph node metastasis by promoting epithelial-mesenchymal transition and VEGF-C secretion · Clinical and Experimental Medicine · 2026 · Same journal
• Global trends in the burden of inflammatory bowel disease from 1990 to 2021: socioeconomic and sex-specific disparities with exploratory mendelian randomization analyses · Clinical and Experimental Medicine · 2026 · Same journal
• Extranodal involvement defines distinct immune-molecular phenotypes and clinical outcomes in diffuse large b-cell lymphoma · Clinical and Experimental Medicine · 2026 · Same journal
• Serum TIMP-1 shows a potential association with metastatic disease in patients with pancreatic cancer: a pilot analysis without a healthy control cohort · Clinical and Experimental Medicine · 2026 · Same journal
• Integrated bioinformatic evaluation unveils a cellular senescence gene signature as a poor prognostic factor in hepatocellular carcinoma · Clinical and Experimental Medicine · 2026 · Same journal
• Population-specific association and risk discrimination utility of the cardiometabolic index for prevalent hypertension–diabetes comorbidity: insights from CHARLS and NHANES · Clinical and Experimental Medicine · 2026 · Same journal
• Beyond polarization: a receptor-centered framework for macrophage function and therapy in skin diseases · Clinical and Experimental Medicine · 2026 · Same journal
• Dissecting PCD-driven molecular landscapes in AML: a multi-omic framework for prognostication and therapeutic targeting · Clinical and Experimental Medicine · 2026 · Same journal
• Thromboembolic risk in subcutaneous versus intravenous immunoglobulin therapy: a systematic review and narrative meta-synthesis · Clinical and Experimental Medicine · 2026 · Same journal
• Neuropeptide Y promotes myocardial fibrosis post myocardial infarction reperfusion through Neuropeptide Y receptor type 1 · Clinical and Experimental Medicine · 2026 · Same journal